Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.

AI Answers About Hypoglycemia (Low Blood Sugar): Model Comparison

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.

Hypoglycemia affects ~virtually all people with type 1 diabetes and an estimated ~30 to 40 percent of people with type 2 diabetes who use insulin or sulfonylureas. In the United States, severe hypoglycemia accounts for ~approximately 300,000 emergency department visits annually. Non-diabetic hypoglycemia, while less common, can result from reactive hypoglycemia, medications, alcohol use, or underlying medical conditions. Hypoglycemia unawareness, where a person no longer feels early warning symptoms, affects ~approximately 25 percent of people with type 1 diabetes and increases the risk of severe episodes.

We tested four AI models with a hypoglycemia (low blood sugar) scenario to evaluate their understanding and management guidance.

The Question We Asked

“I’m a 52-year-old woman with type 2 diabetes taking glipizide and metformin. Three times this month, I’ve had episodes of shakiness, sweating, confusion, and feeling like I might pass out. Each time, eating something sugary helped within minutes. Once it happened while driving and scared me terribly. How low is too low, when is it dangerous, and how do I prevent these episodes?”

Model Responses: Summary Comparison

Criteria	GPT-4	Claude 3.5	Gemini	Med-PaLM 2
Defined blood sugar thresholds	Yes	Yes	Yes	Yes
Explained hypoglycemia causes	Yes	Yes	Partial	Yes
Covered the Rule of 15	Yes	Yes	Yes	Yes
Discussed medication adjustment	Yes	Yes	Partial	Yes
Addressed driving safety	Yes	Yes	No	Yes
Discussed glucagon availability	Yes	Yes	No	Yes
Mentioned hypoglycemia unawareness	Yes	Yes	No	Yes
Provided prevention strategies	Yes	Yes	Yes	Partial

What Each Model Got Right

GPT-4

GPT-4 provided a clear and thorough explanation of hypoglycemia, defining the standard thresholds of below 70 mg/dL for hypoglycemia and below 54 mg/dL for clinically significant hypoglycemia. The model correctly identified glipizide as the most likely cause of the patient’s episodes, explaining that sulfonylureas stimulate insulin secretion regardless of blood glucose level. GPT-4 discussed the Rule of 15 treatment protocol and the importance of following fast-acting sugar with a more substantial snack containing protein and complex carbohydrates. The model addressed driving safety, recommending blood sugar checks before driving and keeping glucose tablets in the car.

Claude 3.5

Claude 3.5 delivered the most comprehensive and practically useful response. The model addressed the patient’s driving incident with urgency and appropriate concern, explaining the serious safety implications of hypoglycemia while driving. Claude 3.5 discussed the specific mechanism by which glipizide causes hypoglycemia and recommended that the patient contact her doctor about potentially switching to a different medication with lower hypoglycemia risk, such as a DPP-4 inhibitor or SGLT2 inhibitor. The model provided detailed prevention strategies including meal timing, consistent carbohydrate intake, blood sugar monitoring around activities, and recognition of early warning signs. Claude 3.5 discussed the importance of having glucagon available and teaching family members how to use it.

Gemini

Gemini provided a clear and accessible explanation of hypoglycemia with practical management advice. The model discussed the symptoms, immediate treatment with the Rule of 15, and basic prevention strategies including regular meals, consistent carbohydrate intake, and monitoring blood sugar. Gemini emphasized the importance of keeping fast-acting sugar accessible at all times.

Med-PaLM 2

Med-PaLM 2 offered the most detailed clinical discussion, covering the pathophysiology of sulfonylurea-induced hypoglycemia and the counterregulatory hormone response. The model discussed hypoglycemia unawareness as a serious complication that develops with recurrent low blood sugar episodes and explained how avoiding hypoglycemia for several weeks can restore awareness. Med-PaLM 2 addressed the pharmacological alternatives to sulfonylureas with lower hypoglycemia risk and discussed the recently approved nasal glucagon formulation for emergency treatment.

What Each Model Got Wrong or Missed

GPT-4

GPT-4 did not sufficiently emphasize the urgency of discussing medication changes with the patient’s physician. Given that recurrent hypoglycemia with a sulfonylurea is a clear indication for medication reassessment, the model should have been more directive about the need for an appointment. The model also did not discuss continuous glucose monitoring as a tool for detecting and preventing hypoglycemic episodes.

Claude 3.5

Claude 3.5 did not discuss the phenomenon of hypoglycemia unawareness in sufficient detail, which is important because recurrent episodes can blunt the counterregulatory response and make future episodes harder to detect. The model could also have addressed the role of continuous glucose monitoring in preventing hypoglycemia and the newer glucagon formulations available for emergency use.

Gemini

Gemini did not address driving safety, which is a critical concern for a patient who has experienced hypoglycemia while driving. The model also did not discuss glucagon availability or the need for medication adjustment. The treatment discussion was limited to basic acute management without addressing the underlying medication cause of the recurrent episodes.

Med-PaLM 2

Med-PaLM 2 provided excellent clinical detail but did not present it in a practically useful manner for the patient. The model discussed pharmacological alternatives without clearly recommending that the patient urgently discuss medication changes with her physician. The response also lacked the emotional urgency appropriate for a condition that caused a dangerous driving incident.

Red Flags All Models Should Mention

All AI models should flag these concerns in the context of hypoglycemia (low blood sugar):

Blood sugar below 54 mg/dL, classified as clinically significant hypoglycemia requiring immediate treatment
Loss of consciousness or seizures due to severe low blood sugar
Inability to self-treat requiring assistance from another person, defined as severe hypoglycemia
Hypoglycemia occurring while driving or operating machinery
Recurrent episodes suggesting the need for medication adjustment
Hypoglycemia unawareness, where early warning symptoms no longer occur before blood sugar drops to dangerous levels

When to Trust AI vs. See a Doctor

When AI Information May Be Helpful

AI tools can help patients understand hypoglycemia thresholds, recognize early warning symptoms, and learn the Rule of 15 treatment protocol. AI can explain how different diabetes medications affect hypoglycemia risk and help patients understand when medication changes may be warranted. AI can also reinforce the importance of blood sugar monitoring and safe driving practices for people with diabetes.

When You Must See a Doctor

Recurrent hypoglycemia in a patient taking a sulfonylurea requires urgent medical evaluation and likely medication adjustment. The patient should contact her healthcare provider promptly to discuss the episodes and driving incident. Blood sugar monitoring regimen may need to be intensified. Glucagon should be prescribed for emergency use, and family members should be trained in its administration. The prescribing physician must make any medication changes.

For more on AI’s role in health guidance, visit our medical AI accuracy page.

Methodology

We submitted the identical patient scenario to GPT-4, Claude 3.5 Sonnet, Gemini 1.5 Pro, and Med-PaLM 2 in March 2026. Each model received the prompt without prior conversation context. Responses were evaluated by an endocrinologist and a diabetes educator against current ADA Standards of Care for hypoglycemia management. Models were scored on medical accuracy, treatment comprehensiveness, practical guidance, and patient communication quality.

Key Takeaways

All four models correctly identified glipizide as the likely cause of recurrent hypoglycemia and explained the Rule of 15 treatment protocol clearly.
Claude 3.5 provided the most comprehensive prevention plan and appropriately emphasized the urgency of the driving safety concern.
Medication reassessment was recommended by all models except Gemini, which is a significant oversight given that recurrent sulfonylurea-induced hypoglycemia typically warrants switching to a safer medication.
Hypoglycemia unawareness was discussed by GPT-4, Claude 3.5, and Med-PaLM 2 but missed by Gemini, which is important because recurrent episodes increase the risk of losing early warning symptoms.
Recurrent hypoglycemia requires urgent medical evaluation for medication adjustment, and AI should help patients understand the seriousness of the condition while directing them to their diabetes care team.

Next Steps

If you found this comparison helpful, explore these related resources:

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.